The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines

G McLean, J Kamil, B Lee, P Moore, TF Schulz, A Muik… - MBio, 2022 - Am Soc Microbiol
The emergence of several new variants of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in recent months has raised concerns around the potential impact on …

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis

WY Au, PPH Cheung - Bmj, 2022 - bmj.com
Objective To evaluate the effectiveness of heterologous and homologous covid-19 vaccine
regimens with and without boosting in preventing covid-19 related infection, hospital …

[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …

APS Munro, L Janani, V Cornelius, PK Aley… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK …

ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

J Li, L Hou, X Guo, P Jin, S Wu, J Zhu, H Pan… - Nature medicine, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and the waning of vaccine-elicited neutralizing antibodies suggests that additional …

Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2. S priming

RSG Sablerolles, WJR Rietdijk… - … England Journal of …, 2022 - Mass Medical Soc
Abstract Background The Ad26. COV2. S vaccine, which was approved as a single-shot
immunization regimen, has been shown to be effective against severe coronavirus disease …

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec …

DM Skowronski, S Setayeshgar, Y Febriani, M Ouakki… - MedRxiv, 2021 - medrxiv.org
ABSTRACT Background The Canadian COVID-19 immunization strategy deferred second
doses and allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by …

[HTML][HTML] Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 …

R Izikson, D Brune, JS Bolduc, P Bourron… - The Lancet …, 2022 - thelancet.com
Background Concomitant seasonal influenza vaccination with a COVID-19 vaccine booster
could help to minimise potential disruption to the seasonal influenza vaccination campaign …

[HTML][HTML] Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice

B Ying, SM Scheaffer, B Whitener, CY Liang… - Cell, 2022 - cell.com
The large number of spike substitutions in Omicron lineage variants (BA. 1, BA. 1.1., and BA.
2) could jeopardize the efficacy of SARS-CoV-2 vaccines. We evaluated in mice the …

Heterologous prime–boost strategies for COVID-19 vaccines

B Sapkota, B Saud, R Shrestha… - Journal of travel …, 2022 - academic.oup.com
Abstract Background/Objective Heterologous prime–boost doses of COVID-19 vaccines
('mix-and-match'approach) are being studied to test for the effectiveness of Oxford …